Summary statistics - quantitative results

EQA round: AP2/24 - Antithrombotic Agents

Deadline: 13.9.2024

Setup: groups - M (measurement principle); minimal size of the groups n = 5

RoM = robust average
SD = standard deviation
CV = coefficient of variation
N_{tot} = total number of the results
N_{out} = number of the results removed before calculation

AV = assigned value
CVP = consensus of all participants
U_{AV} = expanded uncertainty of the assigned value (k = 2)

D_{max} = acceptable difference
LL = lower limit
UL = upper limit
N_{eva} = number of the results assessed
N_{suc} = number of successful results
S_{rel} = relative success

Test / Sample / Group	[unit]	RoM	SD	CV [%]	N_{tot}	N_{out}	Comparability	AV	U_{AV}	D_{max}	LL	UL	N_{eva}	N_{suc}	S_{rel} [%]
Set 1															
(108) **Apixaban**	[µg/L]				46								46	46	100
Sample A1		446	25	5,7	46		CVP	446	9,3	25%	334	558	46	46	100
(2) Chromogenous substrat		446	24	5,4	42	1							42		
Other					4	0							4		
							4x 1								
Sample B1		222	12	5,4	46		CVP	222	4,3	25%	166	278	46	46	100
(2) Chromogenous substrat		221	12	5,5	42	0							42		
Other					4	0							4		
							4x 1								
Set 2															
(109) **Dabigatran**	[µg/L]				38								38	37	97
Sample A2		231	21	9,2	38		CVP	231	8,4	30%	161	301	38	37	97
(1) Coagulometer		237	29	12	23	0							23		
(2) Chromogenous substrat		225	13	5,9	15	0							15		
Sample B2		95	10	11	38		CVP	95	4,1	30%	66,5	124	38	38	100
(1) Coagulometer		99,6	13	13	23	0							23		
(2) Chromogenous substrat		89,8	6,9	7,7	15	0							15		
Set 3															
(110) **Rivaroxaban**	[µg/L]				51								51	50	98
Sample A3		288	16	5,7	51		CVP	288	5,6	25%	216	360	51	51	100
(2) Chromogenous substrat		287	16	5,6	47	0							47		
Other					4	0							4		
							4x 1								
Sample B3		90,5	5,8	6,4	51		CVP	90,5	2	25%	67,8	114	51	50	98
(2) Chromogenous substrat		90,4	5,8	6,5	47	0							47		
Other					4	0							4		
							4x 1								